Aduro Biotech CDMRP Grant for Prostate Cancer Vaccine Development

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces the award of a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense. The grant of $867,846 will be used to complete the preclinical development of a novel therapeutic cancer vaccine for prostate cancer.

Back to news